ScoreWhy is Guiyang Xintian Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 0.80% and Operating profit at -26.41% over the last 5 years
2
The company has declared Negative results for the last 10 consecutive quarters
- NET SALES(HY) At CNY 365.48 MM has Grown at -24.41%
- PRE-TAX PROFIT(Q) At CNY 10.4 MM has Fallen at -67.71%
- NET PROFIT(Q) At CNY 10.41 MM has Fallen at -66.05%
3
With ROE of 2.34%, it has a expensive valuation with a 2.19 Price to Book Value
- Over the past year, while the stock has generated a return of 2.45%, its profits have fallen by -57.2%
- At the current price, the company has a high dividend yield of 0.9
4
Underperformed the market in the last 1 year
- The stock has generated a return of 2.45% in the last 1 year, much lower than market (China Shanghai Composite) returns of 16.01%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Guiyang Xintian Pharmaceutical Co., Ltd. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Guiyang Xintian Pharmaceutical Co., Ltd.
2.45%
0.28
42.02%
China Shanghai Composite
16.01%
1.07
14.97%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.80%
EBIT Growth (5y)
-26.41%
EBIT to Interest (avg)
8.10
Debt to EBITDA (avg)
3.44
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
0.51
Tax Ratio
12.73%
Dividend Payout Ratio
42.11%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.47%
ROE (avg)
8.54%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
93
Industry P/E
Price to Book Value
2.19
EV to EBIT
150.24
EV to EBITDA
58.34
EV to Capital Employed
1.88
EV to Sales
3.96
PEG Ratio
NA
Dividend Yield
0.89%
ROCE (Latest)
1.25%
ROE (Latest)
2.34%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 149.44 MM
RAW MATERIAL COST(Y)
Fallen by -2.14% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at 34.23 %
-23What is not working for the Company
NET SALES(HY)
At CNY 365.48 MM has Grown at -24.41%
PRE-TAX PROFIT(Q)
At CNY 10.4 MM has Fallen at -67.71%
NET PROFIT(Q)
At CNY 10.41 MM has Fallen at -66.05%
ROCE(HY)
Lowest at 0.65%
Here's what is working for Guiyang Xintian Pharmaceutical Co., Ltd.
Operating Cash Flow
Highest at CNY 149.44 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Debt-Equity Ratio
Lowest at 34.23 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -2.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Guiyang Xintian Pharmaceutical Co., Ltd.
Net Sales
At CNY 365.48 MM has Grown at -24.41%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (CNY MM)
Pre-Tax Profit
At CNY 10.4 MM has Fallen at -67.71%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 10.41 MM has Fallen at -66.05%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
